













CDP PROJECTS – ACTIVE

AGENT	TARGET/ TECHNOLOGY	PARTNER	INDICATIONS	FIRST IN HUMAN/ FIRST IN CLASS	DEVELOPMENT STAGE					
					DUE DILIGENCE	EXPLORATORY	PRECLINICAL	TRIAL SET UP	PHASE I	PHASE II
STK-01	HPG-docetaxel		Bladder	First in human●					
TYG100	Vaccine G17, APC		Gastro-oesophageal, pancreatic	First in human●					
BT1718	MT1-MMP		Solid, lung, sarcoma, breast	First in class●					
MEDI3039	Recombinant protein TrailR2		Solid, colorectal, non-small cell lung	First in human●					
ATN658	Antibody uPAR		Solid, colon, breast, lung, melanoma	First in class●					
AST-VAC2	Vaccine LAMP, hTERT		Lung	First in class●					
LY3143921	Cdc7		Solid, colorectal, ovarian	First in human●					
AT13148	AGC, ROCK		Solid	First in class●					
BI-1206	Antibody CD32b, FcγRIIB		Lymphoma, B cell, chronic lymphocytic leukaemia	First in human●					
AZD3965	MCT1		Solid, prostate, non-Hodgkin lymphoma, B cell	First in class●					
DI-B4	Antibody CD19		Lymphoma, B cell, chronic lymphocytic leukaemia	First in human●					
AMG319	p110delta PI3K		Head and neck oropharyngeal	●					

CDP PROJECTS – COMPLETED

AGENT	TARGET/ TECHNOLOGY	ORIGINATING PARTNER	DEVELOPMENT PARTNER	DEVELOPMENT STAGE
NMI-900 (GSK1070916)	Aurora Kinase B			Phase II ready
IMA950	Multi-peptide vaccine			Phase Ib
AZD0424	Src-Abl		Currently in CRT marketing	Phase II ready